Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant

Drugs of Today

Volumn 43, Issue 7, 2007, Pages 461-473

  Beaven, Anne W ^a,b   Shea, Thomas C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; NARCOTIC AGENT; PALIFERMIN; PLACEBO; TACROLIMUS;

AGEUSIA; ANAL COMPLAINT; AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; ERYTHEMA; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; ORAL MUCOSAL DISEASE; PAIN; PANCREATITIS; PARESTHESIA; PATHOGENESIS; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TASTE DISORDER; TONGUE; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FIBROBLAST GROWTH FACTOR 7; HEAD AND NECK NEOPLASMS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; STOMATITIS;

EID: 34548303424     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.7.1119723     Document Type: Review

References (60)

1. Spielberger, R., Stiff, P., Bensinger, W. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351: 2590-8.
2. Bellm, L.A., Epstein, J.B., Rose-Ped, A., Martin, P., Fuchs, H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000, 8: 33-9.
3. Sonis, S.T., Oster, G., Fuchs, H. et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001, 19: 2201-5.
4. Rapoport, A.P., Miller Watelet, L.F., Linder, T. et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999, 17: 2446-53.
5. Nikoletti, S., Hyde, S., Shaw, T., Myers, H., Kristjanson, L.J. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 2005, 14: 750-3.
6. Nottage, M., McLachlan, S.A., Brittain, M.A. et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: A randomized, placebo-controlled trial. Support Care Cancer 2003, 11: 41-7.
7. Gabriel, D.A., Shea, T.C., Serody, J.S. et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 2005, 11: 1022-30.
8. Crawford, J., Tomita, D.K., Mazanet, R., Glaspy, J., Ozer, H. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999, 5: 187-93.
9. Valcarcel, D., Sanz, M.A. Jr., Sureda, A. et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 2002, 29: 783-7.
10. Masucci, G., Broman, P., Kelly, C. et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: A multicenter, open, randomized phase III study. Med Oncol 2005, 22: 247-56.
11. Bensadoun, R.J., Schubert, M.M., Lalla, R.V., Keefe, D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 2006, 14: 566-72.
12. Stiff, P.J., Emmanouilides, C., Bensinger, W.I. et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006, 24: 5186-93.
13. Horsley, P., Bauer, J.D., Mazkowiack, R., Gardner, R., Bashford, J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 2007, 15: 105-9.
14. Shea, T.C., Kewalramani, T., Mun, Y., Jayne, G., Dreiling, L.K. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 3073.
15. Meropol, N.J., Somer, R.A., Gutheil, J. et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. J Clin Oncol 2003, 21: 1452-8.
16. Rosen, L.S., Abdi, E., Davis, I.D. et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006, 24: 5194-200.
17. Brizel, D.M., Herman, T., Goffinet, D. et al. A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor in head & neck cancer patients receiving radiotherapy with concurrent chemotherapy. 43rd ASTRO Annual Meeting, San Francisco 2001, Abst. 67.
18. Brizel, D.M., Le, Q.T., Rosenthal, D. et al. Phase 2 study of recombinant human keratinocyte growth factor in head & neck cancer treated with standard or hyperfractionated irradiation & concurrent chemotherapy. 44th Annual ASTRO Meeting, New Orleans 2002, Abst. 2128.
19. Freytes, C.O., Ratanatharathorn, V., Taylor, C. et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 2004, 10: 8318-24.
20. Schuster, M., Anaissie, E., Hurd, D. et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. 42nd ASCO Annual Meeting, Atlanta 2006, Abst. 6537.
21. Schuster, M., Shore, T., Greenberg, J. et al. Phase I trial of CG53135-05 to prevent mucositis in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT). 41st ASCO Annual Meeting, Orlando 2005, Abst. 6656.
22. Sonis, S.T. A biological approach to mucositis. J Support Oncol 2004, 2: 21-32; discussion 35-6.
23. Scully, C., Sonis, S., Diz, P.D. Oral mucositis. Oral Dis 2006, 12: 229-41.
24. Rubin, J.S., Osada, H., Finch, P.W., Taylor, W.G., Rudikoff, S., Aaronson, S.A. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989, 86: 802-6.
25. Finch, P.W., Rubin, J.S., Miki, T., Ron, D., Aaronson, S.A. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 1989, 245: 752-5.
26. Kepivance® package insert. Amgen Inc., Thousand Oaks, CA, USA, 2005.
27. Ptitsyn, L.R., Al'tman, I.B., Gurov, M.V., Vasil'ev, A.V., Voroteliak, E.A., Terskikh, V.V. Production of recombinant human keratinocyte growth factor in Escherichia coli cells. Bioorg Khim 1998, 24: 523-9.
28. Zia-Amirhosseini, P., Salfi, M., Leese, P. et al. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 2006, 79: 558-69.
29. Zia-Amirhosseini, P., Salfi, M., Elhardt, D. et al. Pharmacokinetics (PK) of 2 dosing regimens of palifermin in patients with hematologic malignancies undergoing high-dose chemoradiotherapy and hematopoietic stem cell transplantation. 47th ASH Annual Meeting and Exposition, Atlanta 2005, Abst. 5294.
30. Gillespie, B., Zia-Amirhosseini, P., Salfi, M. et al. Effect of renal function on the pharmacokinetics of palifermin. J Clin Pharmacol 2006, 46: 1460-8.
31. Bao, S., Wang, Y., Sweeney, P. et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005, 288: L36-42.
32. Chang, Y., Wang, J., Lu, X., Thewke, D.P., Mason, R.J. KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J Lipid Res 2005, 46: 2624-35.
33. Ray, P., Devaux, Y., Stolz, D.B. et al. Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci USA 2003, 100: 6098-103.
34. Potten, C.S., Booth, D., Cragg, N.J. et al. Cell kinetic studies in the murine ventral tongue epithelium: Mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Prolif 2002, 35 (Suppl. 1): 32-47.
35. Styczynski, J., Debski, R., Krenska, A. et al. Keratinocyte growth factor for prophylaxis of oral mucositis in children undergoing hematopoietic stem cell transplantation. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 5247.
36. Spielberger, R., Stiff, P., Emmanouilides, C. et al. Efficacy of recombinant human keratinocyte growth factor in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation-based conditioning - results of a phase 2 trial. 37th ASCO Annual Meeting, Baltimore 2001, Abst. 25.
37. Stiff, P.J., Erder, H., Bensinger, W.I. et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006, 37: 393-401.
38. Cavagna, L., Bonifacio, G., Angelucci, E. et al. Palifermin in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation: The Italian early access program. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 5236.
39. Sonet, A., Bries, G., Meulemans, N. et al. Palifermin treatment in patients receiving high-dose melphalan or BEAM prior to autolgous peripheral blood stem-cell transplantation. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 5241.
40. Sousa, I. , Geraldes, C. Acute enterocolitis incidence in patients with hematological malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support - Palifermin experience. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 5461.
41. Krijanovski, O.I., Hill, G.R., Cooke, K.R. et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999, 94: 825-31.
42. Vanclee, A., Lutgens, L.C., Oving, E.B. et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel non-myeloablative haploidentical transplantation model. Bone Marrow Transplant 2005, 36: 907-15.
43. Rossi, S., Blazar, B.R., Farrell, C.L. et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002, 100: 682-91.
44. Seggewiss, R., Lore, K., Guenaga, F.J., et al. Keratinocyte growth factor increases thymic output of naive T cells after total body irradiation and autologous peripheral blood progenitor cell transplantation in rhesus macaques. 47th ASH Annual Meeting and Exposition, Atlanta 2005, Abst. 187.
45. Min, D., Taylor, P.A., Panoskaltsis-Mortari, A. et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: A new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002, 99: 4592-600.
46. Panoskaltsis-Mortari, A., Taylor, P.A., Rubin, J.S. et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000, 96: 4350-6.
47. Blazar, B.R., Weisdorf, D.J., Defor, T. et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006, 108: 3216-22.
48. Reynolds, CM., Levine, J.E., Uberti, J.P. et al. Keratinocyte growth factor factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease in patients at high risk of aGVHD. 46th ASH Annual Meeting and Exposition, San Diego 2004, Abst. 1228.
49. Nasilowska-Adamska, B., Rzepecki, P., Manko, J. et al. The significance of palifermin (Kepivance) in reduction of oral mucositis incidence and acute graft versus host disease in patients with hematological diseases undergoing HSCT. 48th ASH Annual Meeting and Exposition, Orlando 2006, Abst. 2965.
50. Spielberger, R., Emmanouilides, C., Bensinger, W., Rong, A., Cesano, A., Stiff, P. Long-term survival is comparable between palifermin-treated and placebo-treated patients with hematologic malignancies undergoing high-dose chemotherapy and total body irradiation followed by autologous hematopoietic stem cell transplantation. 47th ASH Annual Meeting and Exposition, Atlanta 2005, Abst. 2925.
51. Bensadoun, R.J., Benezery, K., Dassonville, O. et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006, 64: 983-94.
52. Gibson, R.J., Keefe, D.M., Clarke, J.M. et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002, 50: 53-8.
53. Oelmann, E., Haghgu, S., Kulimova, E. et al. Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol 2004, 25: 1001-12.
54. Ning, S., Shui, C., Khan, W.B., Benson, W., Lacey, D.L., Knox, S.J. Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998, 40: 177-87.
55. Hille, A., Rave-Frank, M., Pradier, O. et al. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003, 79: 119-28.
56. Nguyen, T.N., Zang, X.P., Pento, J.T. Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res 2002, 46: 179-83.
57. Ropiquet, F., Huguenin, S., Villette, J.M. et al. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 1999, 82: 237-43.
58. Okunieff, P., Fenton, C.M., Zhang, L. et al. Fibroblast growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow and oxygenation without significant change in vascular density. In: Dunn, J.F , Swartz, H.M. (Eds.). Oxygen Transport to Tissue XXIV. Ktuwer Academic/Plenum Publishers, New York 2003, 593-601.
59. Okunieff, P., Li, M., Liu, W. et al. Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am J Clin Oncol 2001, 24: 491-5.
60. Zang, X.P., Pento, J.T. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000, 18: 573-80.